Cannabis use in older adults is increasingly common, but the clinical risk profile is distinct from that in younger populations because of age-related pharmacokinetics, multimorbidity, and polypharmacy. The primary psychoactive constituent, Ι4-tetrahydrocannabinol (THC), acts primarily at cannabinoid receptor type 1 (CB1) and type 2 (CB2), which are distributed in the central nervous system and peripheral immune tissues. With aging, changes such as reduced hepatic metabolism, altered body composition, and increased blood-brain barrier vulnerability can increase exposure to THC and its metabolites, amplifying adverse effects. Older adults are therefore particularly susceptible to cannabis-associated falls, cognitive impairment, clinically important drug-drug interactions, and psychiatric complications.
Falls are among the most consistently emphasized safety concerns. THC can impair balance, reaction time, coordination, and visuospatial processing. Sedation and orthostatic hypotension may occur through central nervous system effects and autonomic influences, increasing the likelihood of dizziness and gait instability. These effects are magnified in older adults who already have fall risk from frailty, peripheral neuropathy, vestibular disorders, slowed gait, or sedating medications. Cannabis products, especially high-THC formulations or edibles with delayed onset, can produce prolonged impairment that is difficult for patients to anticipate, thereby increasing injury risk during the critical window when performance is most affected.
Cognitive impairment is another clinically relevant outcome. Cannabis can affect attention, working memory, learning, and executive function. Neurocognitive domains that depend on frontal-subcortical networks and hippocampal signaling can be disrupted by THC-mediated modulation of neurotransmitter release, including glutamatergic and dopaminergic signaling. In older adults, baseline cognitive vulnerability due to mild cognitive impairment, neurodegenerative disease, or vascular brain changes may render cannabis-related cognitive effects more noticeable and harder to compensate for. Chronic use has been associated in observational studies with worsened cognitive performance, while acute use reliably impairs short-term cognition. Importantly, distinguishing reversible intoxication effects from longer-term neurocognitive decline requires careful temporal assessment and clinical context.
Drug interactions are a practical and high-yield concern in aging populations because many older adults take multiple medications with narrow therapeutic indices. Cannabis constituents and cannabinoids can influence cytochrome P450 (CYP) pathways, particularly CYP3A4 and CYP2C9, and can affect drug transporters. This can alter serum concentrations of medications metabolized through these pathways. Clinically, this may translate into increased adverse effects (for example, enhanced sedation) or reduced efficacy (for some cardiovascular or neuropsychiatric drugs). Particular vigilance is warranted with anticoagulants and antiplatelet agents, antiepileptics, opioids, benzodiazepines, hypnotics, and other centrally acting depressants. Concomitant use may compound respiratory depression risk, gait instability, confusion, and delirium.
Psychiatric complications are also a key element of the risk discussion. THC is associated with anxiety exacerbation in some users and can precipitate panic symptoms, paranoia, or psychotic-like experiences, particularly at higher doses and in those with a personal or family history of psychotic disorders, bipolar disorder, or severe anxiety. Mechanistically, THC-induced changes in dopamine signaling and salience attribution may destabilize psychosis-relevant circuits. Older adults may present with atypical symptom patterns, including confusion and mood lability that can be misattributed to age-related cognitive decline or medication side effects. Furthermore, cannabis can worsen underlying mood disorders and can contribute to treatment nonadherence if intoxication or cognitive effects interfere with daily functioning.
From a clinical decision-making standpoint, risk should be individualized. Clinicians should ask about product type (flower, concentrate, edible), dose, frequency, time of last use, and whether the patient drives or performs hazardous activities. Screening should include fall history, cognitive baseline, psychiatric history, and a complete medication inventory. When cannabis is used therapeutically, harm reduction strategies are essential: start low and go slow, avoid high-THC concentrates, prefer formulations with known dosing control (and caution with edibles due to delayed onset), and schedule use away from times when balance is needed. Patients should be monitored for sedation, orthostasis, new confusion, worsening anxiety, and any emergence of hallucinations or suspiciousness.
Public health messaging for older adults should emphasize that cannabis is not risk-free, especially in the context of multimorbidity and polypharmacy. The best evidence for causality continues to rely on a mix of observational and mechanistic data, but the constellation of falls, cognitive impairment, drug interactions, and psychiatric complications is sufficiently documented to warrant careful counseling and shared decision-making. Source: Betsy Kosheff (Dr. Peter Grinspoon event discussion; Creator: @betsykosheff).
Betsy Kosheff: Dr. Peter Grinspoon is speaking at an event sponsored by a cannabis dispensary. Older adults should also hear about the documented risks of cannabis use in aging populations, including falls, cognitive impairment, drug interactions, and psychiatric complications. But they. #breaking
— @betsykosheff May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
